Abstracts tagged "Atherosclerosis"

Abstract Number: 2414 • ACR Convergence 2024
A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry
Alma Aveytia Camacho¹, Rakesh Gullapelli², Vineetha Philip³, Soudabeh Daliri¹, Ruba Memon⁴, Helene DiGregorio², Lily Romero Karam², Kanika Monga³, Eleonora Avenatti², Khurram Nasir² and Myriam Guevara¹, ¹Houston Methodist, Houston, TX, ²Houston Methodist Hospital, Houston, TX, ³Houston Methodist Hospital, Sugar Land, TX, ⁴Houston Methodist, Missouri City, TX
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased prevalence of cardiovascular risk factors (RFs), which predispose to higher risk of premature atherosclerotic cardiovascular disease…
Abstract Number: 0156 • ACR Convergence 2024
Psoriasis and Psoriatic Arthritis Are Independent Risk Factors for Non-Fatal Cardiovascular Admissions in Transition-Age Young Adults
Anurag Goel¹, Joshua Tanzer² and Vinit Gilvaz³, ¹The Warren Alpert Medical School of Brown University, Providence, RI, ²Lifespan Biostatistics, Epidemiology, Research Design, and Informatics Core, Providence, RI, ³The Warren Alpert Medical School of Brown University, East Providence, RI
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated…
Abstract Number: 0229 • ACR Convergence 2024
An Early Inflammatory Cardiac Phenotype and Association with Future Coronary Plaque Burden in Rheumatoid Arthritis
Brittany Weber¹, Feng Liu², Mary Jeffway², Dana Weisenfeld², Gregory McDermott³, Elena Massarotti², Jonathan Coblyn², Michael Weinblatt⁴, Marcelo Di Carli², Damini Dey⁵ and Katherine Liao², ¹Brigham and Women's Hospital, DEDHAM, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital, Brookline, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Cedars-Sinai Medical Center, Los Angeles
Background/Purpose: Patients with RA are at increased risk of cardiovascular disease (CVD) compared to the general population. In a prior study of RA patients with…
Abstract Number: 0611 • ACR Convergence 2024
Subclinical Atherosclerosis Is Associated with Future Cardiovascular Events in Systemic Lupus Erythematosus Patients at Apparent Low Risk for Cardiovascular Disease: A Longitudinal Prospective Study
Arthur Mageau¹, Marie-Paule Chauveheid², Chrystelle Francois², Thomas Papo¹ and Karim Sacré¹, ¹Université Paris Cité, Paris, France, ²Assistance Publique Hôpitaux de Paris, Paris, France
Background/Purpose: Cardiovascular events (CVE) are the leading cause of mortality for patients living with systemic lupus erythematosus (SLE). Besides the traditional cardiovascular risk factors, the…
Abstract Number: 0838 • ACR Convergence 2024
The Mechanistic Impact of IgA anti-beta-2 Glycoprotein I on Accelerated Atherosclerosis in Primary APS
Kavya Sugur¹, Emily Chong¹, Srilakshmi Yalavarthi², Katarina Kmetova³, Lyndsay Kluge¹, Wenying Liang², Cyrus Sarosh⁴, NaveenKumar Somanathapura K², Jacqueline Madison², Ajay Tambralli², Jason Knight² and Yu Zuo², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, ⁴University of Michigan, Temperance, MI
Background/Purpose: Antiphospholipid syndrome (APS) is an acquired thrombo-inflammatory disease characterized by persistent antiphospholipid antibodies (aPL). APS patients experience significant morbidity and mortality, much of which…
Abstract Number: 1157 • ACR Convergence 2024
Reduced Statin Use in Patients with Autoimmune Myopathies and Systemic Lupus Erythematosus Compared to Rheumatoid Arthritis and Non-Inflammatory Diseases
Shane Cameron, Liam O'Neil, Annaliese Tisseverasinghe and Christine Peschken, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatic diseases such as autoimmune myopathy (AIM), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) confer an increased risk for atherosclerotic disease. The 3-hydroxy-3-methylglutaryl-coenzyme…
Abstract Number: 1345 • ACR Convergence 2024
Long-term Changes in Coronary Calcium Score Levels Among Patients with Rheumatoid Arthritis: A Cohort Study
Cristina Corrales Selaya¹, Nuria Vegas Revenga², Carmen Secada Gómez³, Jose Antonio parra-Blanco⁴, Virginia Portilla-González⁴, Ricardo Blanco-Alonso⁵, Miguel Angel Gonzalez-Gay⁶, ivan Ferraz-Amaro⁷ and alfonso Corrales-Martínez⁸, ¹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ²Hospital Galdakao- Usansolo, Galdakao, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁶University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Canarias, Spain, ⁸Hospital Universitario Marques de Valdecilla, Santander, Spain
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of subclinical cardiovascular (CV) disease and, consequently, a higher incidence of CV events, compared to the…
Abstract Number: 1347 • ACR Convergence 2024
Interest of DAS28-γGT in Assessing Cardiovascular Risk Activity in Rheumatoid Arthritis in Routine Practice
Manon Lesturgie-Talarek¹, Fabien Picard², sabrina hamroun³, Malika Saadi², Camille Macher⁴, Aude Deloumeau³, Karim Wahbi², jacques Blacher⁴, Yannick Allanore⁵ and Jérôme Avouac⁶, ¹Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ²Cardiology Department - Cochin Hospital, Paris, France, ³Rheumatology Department - Cochin Hospital, Paris, France, ⁴Cardiology Department, Hôtel Dieu Hospital, Paris, France, ⁵Université Paris Cité, Paris, France, ⁶Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular (CV) mortality, linked to systemic inflammation and the presence of associated CV risk factors.…
Abstract Number: 1361 • ACR Convergence 2024
The Effect of Disease Activity on Cardiovascular Risk Varies According to Rheumatoid Factor and Anticitrullinated Protein Antibody Status in Patients with Rheumatoid Arthritis
George Karpouzas¹, Virginia Pascual Ramos², Elena Myasoedova³, Miguel Angel Gonzalez-Gay⁴, alfonso Corrales-Martínez⁵, Solbritt Rantapaa-Dahlqvist⁶, Petros Sfikakis⁷, Patrick Dessein⁸, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawy¹¹, Piet Van RIel¹², Irazu Contreras Yanez¹³, Iris Jazmín Colunga Pedraza¹⁴, Dionicio Galarza-Delgado¹⁵, jose Ramon Azpiri-Lopez¹⁶, Anne Grete Semb¹⁷, Durga P Misra¹⁸, Patrick Durez¹⁹, Brian Bridal Logstrup²⁰, Ellen Margrethe Hauge²¹, George Kitas²² and Sarah Ormseth²³, and ATACC-RA, ¹Harbor-UCLA Medical Center, Torrance, CA, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Federal District, Mexico, ³Mayo Clinic, Rochester, MN, ⁴University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁶Umeå University, Umeå, Sweden, ⁷Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, ⁸University of Witwatersrand, Johannesburg, South Africa, ⁹University of Witwatersrand, Johanessburg, South Africa, ¹⁰University of Mannitoba, Winnipeg, Canada, ¹¹University of Mannitoba, Winnipeg, MB, Canada, ¹²Radboud University Medical Center, Nijmegen, Netherlands, ¹³Instituto Nacional de las Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹⁴Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁵UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ¹⁶Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ¹⁷Diakonhjemmet Hospital, Oslo, Norway, ¹⁸Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁹UCLouvain, Louvain, Belgium, ²⁰University of Aarhus, Aarhus, Denmark, ²¹Aarhus Universitetshospital, Aarhus, Denmark, ²²The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ²³The Lundquist Institute, Torrance, CA
Background/Purpose: Rheumatoid arthritis (RA) activity associates with cardiovascular (CV) risk. Anticitrullinated protein antibodies (ACPA) were linked to higher activity and lower remission rates. Treatment responses…
Abstract Number: 1557 • ACR Convergence 2024
Estimation of Cardiovascular Risk in Patients with Systemic Sclerosis – Accuracy of Tools Based on SCORE and Its Modifications Compared to Ultrasound Examination of Subclinical Atherosclerosis
Sabína Oreská¹, Aneta Prokopcová², Hana Storkanova¹, Jaroslav Kudlicka³, Vladimir Tuka⁴, Ondrej Mikes⁴, Zdislava Krupickova⁴, Martin Satny⁴, Eva Chytilova⁴, Jan Kvasnicka⁴, Maja Spiritovic⁵, Barbora Hermankova⁶, Petr Cesak⁷, Marian Rybar⁸, Karel Pavelka⁹, Ladislav Šenolt², Radim Becvar¹, Jiří Vencovský², Michal Vrablik⁴ and Michal Tomcik¹, ¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, ⁵Institute of Rheumatology, Prague, Czech Republic, Prague, ⁶Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ⁷Department of Human Movement Laboratory, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, ⁸Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic, Kladno, ⁹Institute of Rheumatology and Charles University, Praha, Czech Republic
Background/Purpose: Patients with systemic sclerosis (SSc) have increased cardiovascular (CV) risk due to accelerated atherosclerosis (ATS) caused by systemic inflammation, and vascular impairment. To date,…
Abstract Number: 1565 • ACR Convergence 2024
Prevalence and Risk Factors of Lower Extremities Arterial Disease in Systemic Sclerosis: Preliminary Data from a Single Centre Multidisciplinary Study
Maria-Grazia Lazzaroni¹, Paolo Baggi², Liala Moschetti¹, Eleonora Pedretti³, Elda Piovani¹, Claudia Barison¹, Emma Manzoni⁴, Franco Franceschini¹, Stefano Bonardelli² and Paolo Airò¹, ¹Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ²Vascular Surgery Unit, ASST Spedali Civili of Brescia, University of Brescia, Italy, Brescia, Italy, ³Scleroderma Unit, Rheumatology Unit, ERN ReCONNET, ASST Spedali Civili and University of Brescia; Italy, Brescia, Italy, ⁴University of Brescia, Brescia, Italy
Background/Purpose: Microvascular changes represent a key step of pathogenic process in Systemic Sclerosis (SSc). However, SSc has been demonstrated to carry an increased risk of…
Abstract Number: 1745 • ACR Convergence 2024
Use of Statins and Its Association with Major Adverse Cardiovascular Outcomes with Tofacitinib versus TNF Inhibitors in a Risk-Enriched Population of Patients with Rheumatoid Arthritis
Jon Giles¹, christina Charles-Schoeman², Maya H. Buch³, Maxime Dougados⁴, Zoltan Szekanecz⁵, Ted Mikuls⁶, Steven R Ytterberg⁷, Gary G Koch⁸, Kenneth Kwok⁹, Mary Jane Cadatal¹⁰, Sujatha Menon¹¹, Yan Chen¹², Annette M Diehl¹², Jose L Rivas¹³, Arne Yndestad¹⁴ and Deepak L Bhatt¹⁵, ¹Cedars Sinai Medical Center, Los Angeles, CA, ²UCLA Medical Center, Santa Monica, CA, ³Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ⁴Université de Paris; Department of Rheumatology, Hôpital Cochin; Assistance Publique-Hôpitaux de Paris; and INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France, ⁵Department of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁸Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁹Pfizer Inc, New York, NY, ¹⁰Pfizer Inc, Manila, Philippines, ¹¹Pfizer Inc, Groton, CT, ¹²Pfizer Inc, Collegeville, PA, ¹³Pfizer SLU, Madrid, Spain, ¹⁴Pfizer Inc, Oslo, Norway, ¹⁵Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: ORAL Surveillance (NCT02092467; a post-authorization safety study of tofacitinib 5 and 10 mg twice daily [BID] vs TNF inhibitors [TNFi]) found higher incidence of…
Abstract Number: 2221 • ACR Convergence 2024
Association Between Serum Uric Acid/Serum Creatinine Index and Carotid Plaque in Patients with Rheumatoid Arthritis
Andrea Guajardo Aldaco¹, Dionicio Galarza-Delgado², Iris Jazmín Colunga Pedraza¹, jose Ramon Azpiri-Lopez³, Jesus Cardenas-de la Garza⁴, Rosa Icela Arvizu-Rivera¹, Maria F. Elizondo-Benitez⁵, Valeria Gonzalez-Gonzalez⁶ and Diego Salcedo-Almanza⁷, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ³Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁵Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁷Division of Radiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease. The serum uric acid/serum creatinine ratio (SUA/SCr), which represents uric acid levels in the blood…
Abstract Number: 2235 • ACR Convergence 2024
The Updated PREVENT (Predicting Risk of CVD EVENTs) Algorithm Is Not Able to Indicate Subclinical Coronary or Carotid Atherosclerosis Better Than the Traditional Pooled Cohort Equations in Rheumatoid Arthritis
J. Alex B. Gibbons¹, Joan Bathon² and Jon Giles³, ¹Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ²Columbia University, NEW YORK, NY, ³Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: Patients with RA are at increased risk of atherosclerotic cardiovascular disease (ASCVD), yet traditional 10-year CVD risk calculators—such as the 2013 Pooled Cohort Equations…
Abstract Number: 2239 • ACR Convergence 2024
Age, Seropositivity and Inflammation Determine Risk versus Benefit of Endogenous Estrogens on Coronary Atherosclerosis in Rheumatoid Arthritis
George Karpouzas¹, Bianca Papotti², Sarah Ormseth³, Marcella Palumbo², Elizabeth Hernandez³, Matthew Budoff⁴ and Nicoletta Ronda², ¹Harbor-UCLA Medical Center, Torrance, CA, ²University of Parma, Parma, Italy, ³The Lundquist Institute, Torrance, CA, ⁴Harbor-UCLA Medical Center and the Lundquist Institute for Biomedical Innovation, Torrance, CA
Background/Purpose: Endogenous estrogens (E) appear cardioprotective in women in the general population. Yet, proinflammatory effects were described in chronic autoimmune diseases depending on stage, cell-type…

1
2
3
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].